WS #10944

The dominant signal in this window is the continued escalation of US-Iran tensions, with multiple sources (Bluesky posts, Seeking Alpha, Bloomberg) reporting that the US and Iran have traded strikes, stoking concerns over a broader conflict and Strait of Hormuz traffic. This is corroborated by Polymarket events on Hormuz traffic normalization and oil price spikes. Separately, Ukraine's drone strike campaign against Russian oil refineries continues, with AP, Bluesky posts, and video footage confirming a strike on the Slavyansk refinery in Krasnodar Krai, and Putin acknowledging a 'difficult period'. This is escalating. BridgeBio (BBIO) announced positive Phase 3 PROPEL 3 trial results for infigratinib in achondroplasia, published in NEJM, with plans to submit NDA in Q3 2026. This is a high-significance positive for BBIO. The US-Iran strikes and Ukraine refinery strikes are the most actionable for energy markets, while the BBIO news is a standalone positive for biotech. The narrative arc for US-Iran is ESCALATING, for Ukraine-Russia is ESCALATING.